Updated JIA Recommendations Unveiled

VBCR - April 2014, Volume 3, No 2 - Juvenile Idiopathic Arthritis
Phoebe Starr

New recommendations for juvenile idiopathic arthritis (JIA) were published in 2013, updating the previous set of recommendations from 2011 (Ringold S, et al. Arthritis Care Res [Hoboken]. 2013;65:1551-1563). The recommendations encompass 3 common phenotypes of JIA and incorporate the following agents not included in the previous guidelines: canakinumab (Ilaris) and rilonacept (Arcalyst), both anti–interleukin (IL)-1 agents, and the anti–IL-6 agent tocilizumab (Actemra).

“Systemic JIA is one of the most difficult categories of JIA to treat, and the updated recommendations now include first-line and second-line treatment recommendations for children with this disease,” said Sarah Ringold, MD, MS, Seattle Children’s Hospital and the University of Washington School of Medicine, Seattle. Dr Ringold and Pamela Weiss, MD, The Children’s Hospital of Philadelphia and University of Pennsylvania’s Perelman School of Medicine, Philadelphia, were coprincipal investigators for the 2013 treatment recommendations.

Drs Ringold and Weiss and colleagues reviewed the literature to develop the new JIA recommendations using the RAND/UCLA Appropriateness Method to develop evidence-based recommendations by determining interventions that provide a health benefit exceeding that of health risk by a wide margin. The recommendations took about a year to develop and were voted on by an American College of Rheumatology task force panel of pediatric rheumatologists and researchers. The updated recommendations differ in several ways from the 2011 version:

  • The phenotypes are different
  • Previous risk stratification was not used
  • Anakinra (Kineret), nonsteroidal anti-inflammatory drugs (NSAIDs), and systemic glucocorticoids are still recommended as initial therapeutic options for patients with active systemic features, based on slightly different disease activity parameters
  • Methotrexate/leflunomide are now an initial therapeutic option for systemic JIA without systemic features but active arthritis. Previously, all children had to have up to 1 month of NSAIDs plus or minus intra-arterial injection
  • Canakinumab and tocilizumab are now considered additional therapeutic options for continued disease activity.

The new recommendations also incorporate repeat tuberculosis testing for all children with JIA and for children on biologics with an initial negative scan. Repeat testing can be undertaken at any point if the risk changes from moderate to high.

Anakinra is now an option for first-line treatment of patients with active systemic features and synovitis, and patients with JIA and features of macrophage activation syndrome—a potentially fatal complication occurring in about 10% of JIA patients. Cana­kinumab and tocilizumab are recommended as second-line options for patients with active systemic features and synovitis. Anakinra and tociliz­umab are also recommended as options for second-line treatment for patients without active systemic features but with active synovitis.

These recommendations provide guidance for healthcare professionals who treat JIA for appropriate initiation of therapeutic agents, and they are not intended to supplant individualized patient care, the investigators emphasized, because phenotypes and patient scenarios cannot encompass all possible presentations of JIA.

The authors note that the updated guidelines have several limitations, including no validated disease activity score; low levels of evidence for many recommendations; and no specific dose, route, or tapering for glucocorticoid administration.

Related Items
Tocilizumab Demonstrates Success in the Treatment of Patients with Giant Cell Arteritis
Phoebe Starr
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Giant Cell Arteritis
Rituximab Maintenance Outshines Azathioprine for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Phoebe Starr
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Vasculitis
Depression Worsens Outcomes in Juvenile Idiopathic Arthritis
Alice Goodman
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Juvenile Idiopathic Arthritis
Cost of Drugs and Affordability Don’t Always Jibe
Phoebe Starr
VBCC - July 2016, Vol 7, No 6 published on July 13, 2016 in Value in Oncology
Usefulness of Vitamin D Supplementation Questioned in Patients with Knee Osteoarthritis
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Osteoarthritis
Baricitinib Effective in Patients with Refractory Rheumatoid Arthritis
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Rheumatoid Arthritis
Vaccine Uptake Remains Low in Patients with RA
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Health & Wellness
Age, Smoking History Are Risk Factors for Early Organ Damage in Patients with SLE
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Lupus
IL-6 Inhibitor Shows Promise in Patients with PsA
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Psoriatic Arthritis
ESR1 Mutations Predict Worse Survival in ER-Positive Advanced Breast Cancer
Phoebe Starr
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Personalized Medicine
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology